A Canadian group examined the gut microbiome functional diversity and potential by metagenomic analysis of stool samples from 20 patients ≤21 years old (mean age 16.1 years) with paediatric-onset MS and from 20 matched controls. Exposure to antibiotics or corticosteroids 30 days prior to sampling was not allowed. MS patients were either DMT-naïve (n=8) or used interferon-beta or glatiramer acetate (n=12).
There were no significant differences in functional alpha-diversity by disease or DMT status. However, differential analysis of metabolic pathways revealed that MS patients exhibited higher Archaea-related methanogenesis, flavin biosynthesis (producing vitamin B and flavin cofactors), viral activity, metabolism of heavy metals, and degradation of L-glutamate (which produces the short-chain fatty-acid propionate). These differences were not significant for the DMT-naïve versus DMT-exposed MS patients. Homolactic fermentation (lactate production, associated with anti-inflammatory effects) and bacterial carbohydrate degradation were lower in MS patients than in controls. In patients using a DMT, an enrichment of pathways involved in promoting CNS remyelination was observed versus DMT-naïve MS patients. For example, choline biosynthesis was enriched in DMT-exposed patients (log-fold change 21; 95% CI 12–29; P<0.0001).
- Mirza A, et al. Functional survey of the pediatric multiple sclerosis microbiome. MSVirtual 2020, Abstract PS10.03.
© 2023 The Author(s). Published by Medicom Medical Publishers.
User license: Creative Commons Attribution – NonCommercial (CC BY-NC 4.0)
Posted on
Previous Article
« Modulating BTK-dependent inflammatory signalling in microglia Next Article
Safety and efficacy of cladribine, glatiramer acetate, and more »
« Modulating BTK-dependent inflammatory signalling in microglia Next Article
Safety and efficacy of cladribine, glatiramer acetate, and more »
Table of Contents: MS Virtual 2020
Featured articles
COVID-19 and MS
Biomarkers
Treatment Strategies and Results
Management of progressive MS with approved DMT
Novel Treatment Directions
Neuromyelitis Optica Spectrum Disorders
Miscellaneous Topics
Related Articles

November 1, 2021
ECTRIMS 2021 Highlights Podcast
December 9, 2021
T2 lesions independently predict early conversion to SPMS
November 5, 2020
Ocrelizumab benefits maintained in primary progressive MS
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy